DOI: 10.1024/0300-9831.75.1.3
Through this mechanism, individuals may find it easier to adhere to weight-loss plans, making semaglutide a powerful ally in the battle against obesity
Moreover, a single nucleotide polymorphism related to an elevated plasma SHBG concentration has been found to correlate with a reduced risk of diabetes [33]
Additionally, reducing sugar intake may help manage blood glucose levels, potentially decreasing the risk of UTIs in diabetic patients
The mechanisms driving it
Antiinflammatory actions of glucagon-like peptide-1based therapies beyond metabolic benefits Text PDF Abstract Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver disease, arthritis, and both substance use and neurodegenerative disorders